Sonnet BioTherapeutics Holdings Inc (NASDAQ:SONN)’s traded shares stood at 0.34 million during the last session, with the company’s beta value hitting 0.44. At the close of trading, the stock’s price was $2.10, to imply an increase of 22.81% or $0.39 in intraday trading. The SONN share’s 52-week high remains $18.72, putting it -791.43% down since that peak but still an impressive 20.95% since price per share fell to its 52-week low of $1.66. The company has a valuation of $1.76M, with an average of 0.17 million shares in intraday trading volume over the past 10 days and average of 469.75K shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Sonnet BioTherapeutics Holdings Inc (SONN), translating to a mean rating of 1.00. Of 2 analyst(s) looking at the stock, 0 analyst(s) give SONN a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 2 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -5.52.
Sonnet BioTherapeutics Holdings Inc (NASDAQ:SONN) trade information
After registering a 22.81% upside in the last session, Sonnet BioTherapeutics Holdings Inc (SONN) has traded red over the past five days. The 5-day price performance for the stock is -18.29%, and -43.70% over 30 days. With these gigs, the year-to-date price performance is -84.91%. Short interest in Sonnet BioTherapeutics Holdings Inc (NASDAQ:SONN) saw shorts transact 35196.0 shares and set a 0.03 days time to cover.
Sonnet BioTherapeutics Holdings Inc (SONN) estimates and forecasts
Looking at statistics comparing Sonnet BioTherapeutics Holdings Inc share performance against respective industry, we note that the company has outperformed competitors. Sonnet BioTherapeutics Holdings Inc (SONN) shares are -84.56% down over the last 6 months, with its year-to-date growth rate higher than industry average at 91.12% against 17.50%. The rating firms project that company’s revenue will shrink -100.00% compared to the previous financial year.
SONN Dividends
Sonnet BioTherapeutics Holdings Inc has its next earnings report out in January. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Sonnet BioTherapeutics Holdings Inc (NASDAQ:SONN)’s Major holders
Sonnet BioTherapeutics Holdings Inc insiders hold 4.22% of total outstanding shares, with institutional holders owning 0.61% of the shares at 0.64% float percentage. In total, 0.61% institutions holds shares in the company.
